Oligoclonal T-Cell receptor usage of melanocyte differentiation antigen-reactive T cells in stage IV melanoma patients

David Schrama, Mads Hald Andersen, Patrick Terheyden, Louise Schrøder, Lars Østergaard Pedersen, Per Thor Straten, Jü rgen C. Becker

    26 Citations (Scopus)

    Abstract

    Ex vivo ELISPOT analysis of peripheral blood lymphocytes obtained from stage IV melanoma patients demonstrated reactivity against peptides derived from MART-1 and gp100. However, the number of reactive T cells was < 1% that of total lymphocytes as detected by flow cytometry using tetrameric MHC/peptide complexes. Despite this low frequency, we were able to directly isolate these populations ex vivo by means of magnetic beads coated with MHC/peptide complexes and to subject these cells to T-cell receptor clonotype mapping. This analysis revealed that the MART-1/A*0201- and gp100/A*0201-reactive T-cell populations are composed of oligoclonal T cells that engage several T-cell receptor β chain families. Longitudinal studies using this approach may result in a better correlation between T-cell reactivity and the course of neoplastic disease.

    Original languageEnglish
    JournalCancer Research
    Volume61
    Issue number2
    Pages (from-to)493-496
    Number of pages4
    ISSN0008-5472
    Publication statusPublished - 15.01.2001

    Fingerprint

    Dive into the research topics of 'Oligoclonal T-Cell receptor usage of melanocyte differentiation antigen-reactive T cells in stage IV melanoma patients'. Together they form a unique fingerprint.

    Cite this